ArticleFrontiers in pharmacology2025
Ineffectiveness of tirzepatide in mitigating Doxorubicin-induced oxidative stress and cognitive deficits in a rat model.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Doxorubicin (DXN) is widely utilized for the treatment of various cancer types. However, prolonged DXN administration induces vascular impairment and neurological effects, including cognitive deficits. Here, we investigated the efficacy of tirzepatide (TIR), an antidiabetic agent that improve cognitive function in diabetic rats, in alleviating cognitive impairment in DXN-treated rats. Forty female Wistar rats were allocated to four experimental groups: Control, DXN (5 mg/kg body weight (BW)), TIR (1.35 mg/kg BW), and DXN + TIR (5 mg DXN/kg BW followed by 1.35 mg TIR/kg BW). The compounds were injected intraperitoneally over four cycles. Mortality rates, alterations in body weight (BW), behavior, and oxidative stress markers were evaluated. The mortality rates in the control and TIR groups remained 0%, whereas those in the DXN and DXN + TIR groups were 30% and 40%, respectively. A decline in body weight was detected in rats treated with DXN and DXN + TIR, significantly relative to those in the control and TIR groups. Behavioral assessments revealed that subjects administered with DXN showed impairments, as evidenced by their performance in the Y-maze, MORT, and EPMT tasks. Furthermore, the addition of TIR did not alleviate these impairments. Superoxide dismutase (SOD) and glutathione peroxidase (GPx) levels were diminished in the DXN and DXN + TIR groups although not changes in catalase, whereas reactive oxygen species (ROS), lipid peroxidation, and malondialdehyde (MDA) levels were increased relative to those in the control group. Additionally, the functionality of mitochondrial complex-I was found to be compromised in DXN and DXN + TIR in comparison to the control group. In conclusion, the findings demonstrate that DXN induces neurotoxicity and cognitive impairments through the mechanism of increased oxidative stress. Furthermore, the concurrent administration of TIR did not mitigate the neurotoxic effects, as evidenced by persistent oxidative stress and cognitive deficits.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.